Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Allos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
Allos Therapeutics, 05/27/09
Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The Company also announced that the FDA has granted the NDA priority review status and established a Prescription Drug User Fee Act date of September 2009 for a decision regarding approval of the NDA. Priority review designation is assigned to drugs that have the potential to provide a significant improvement compared to marketed products or provide a safe and effective therapy where no satisfactory therapy exists.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/22/09
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09
FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 11/02/09
Covidien Receives FDA Approval for Oral Transmucosal Fentanyl Citrate Product
Covidien, 11/05/09
Sponsor
Article Search
Sponsor


See Latest Articles


